MOLEFY PHARMA
Contact information
Molefy Pharma SL
Tania Ortuño - Head of Operations
Camino de las Mantecas s/n
San Cristóbal de la Laguna - 38320
Santa Cruz de Tenerife
+34 630 188 986
Areas of activities
- Biodrugs
- Biomarkers
- Drug development
- Drug discovery
- Musculoskeletal system
- Genetic and rare diseases
- Central nervous system
Molefy Pharma is a biotechnology spin-off born from the collaboration between Arquimea and the CSIC, dedicated to advancing innovative and groundbreaking treatments for neurodegenerative diseases. Our most advanced molecule will enter human clinical trials in 2026 as a potential drug for Amyotrophic Lateral Sclerosis (ALS).
Our mission is clear: to develop a therapy that not only slows down, but reverses disease progression, bringing real hope to patients and their families.
Products and services
Biotechnology; small molecules for neurodegenerative diseases; biomarkers.
Areas of interest for future collaborations
Pharmaceutical companies; research centers; universities; biotechnology companies; scientific associations; patient associations.